# Healthcare Podcast Weekly Digest: April 27 – May 1, 2026

> Healthcare sector podcast and news synthesis for April 27 – May 1, 2026. Eli Lilly's blowout Q1 and the Foundayo oral GLP-1 launch, UnitedHealth's turnaround quarter, the FDA's 503B compounding crackdown, and a biopharma M&A market running its hottest in years.


## Healthcare Podcast Weekly Digest

### Week of April 27 – May 1, 2026

```request-access
variant: ghost
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Opening Summary

It was a defining week for the healthcare sector, dominated by Eli Lilly's blowout Q1 print (revenue +56% to $19.8B, FY26 guidance raised to $82–85B) and the early read on Foundayo (orforglipron), the first oral GLP-1 pill approved in the US, with management disclosing >20,000 patients started and >80% new to GLP-1 therapy. UnitedHealth's reset-and-raise quarter (now on Goldman's Conviction List with a $435 PT) catalyzed a broad managed-care relief rally, while the FDA's April 30 proposal to exclude semaglutide/tirzepatide/liraglutide from the 503B bulks list effectively closes the door on legal mass-scale compounding. Underneath the headlines, biopharma M&A remains "the hottest in years" (4–5 deals already > $5B in 2026 vs. zero in all of 2024), with Lilly alone closing three $1B+ deals plus seven alliances in Q1.

---

## Key People This Week

| Speaker | Affiliation | Key Quote / Take |
| --- | --- | --- |
| **Dave Ricks** | CEO, Eli Lilly | "More than 20,000 people have started taking Foundayo" with ">80% new to GLP-1." Q1 revenue +56%; FY26 guide raised to $82–85B. (The Readout Loud, Apr 30) |
| **Asad Haider** | Head of Healthcare, Goldman Sachs | LLY "down about almost 18% on the year vs. US Pharma about flat." On Foundayo consensus: "We are very comfortable with [it], but investors need to be convinced." Industry M&A firepower ~"$650 billion." (Closing Bell, Apr 27) |
| **Bobby Hunter** | Chief of Government Programs, UnitedHealth | On BALANCE Model GLP-1 coverage: "We'd like to find a path to yes there on coverage over time, but there are some notable challenges and outstanding questions with the currently planned structure." (thefly, Apr 21) |
| **Tim Noel** | CEO, UnitedHealthcare | Standardizing electronic prior authorization across >50% of PA volume, scaling to >70% by year-end 2026. (thefly, Apr 24) |
| **Richard Francis** | CEO, Teva | "We set out…to convert Teva from a pure play generics company to an innovative world-class biopharma company." Q1 innovative revenue +41%; Austedo $578M (+41% YoY). First M&A in 10 years (Emilex). (CNBC Money Movers, Apr 29) |
| **Bill Roegge** | Partner, Cooley | "It's the hottest we've seen the biopharma deal market in at least a few years…there's been 4 or 5 [deals >$5B] just this year. The XBI was up 36% in 2025 versus only 18% for the S&P." (Citeline, Apr 22) |
| **Brian Roberts** | Partner, Venrock (Colonia lead investor) | On in vivo CAR-T vs. ex vivo: "Why would [ex vivo autologous] have any place in the armamentarium…if in vivo was safe and efficacious and cheaper and had much higher margins?" (The Readout Loud, Apr 23) |
| **Sabina Hemi** | Founder, GLP Winner | "All B's are going away from GLP-1 compounding…we're going to see delays on compounded prescriptions getting filled, period." (On The Pen, Apr 23) |
| **Adam Feuerstein / Elaine Chen / Allison DeAngelis** | STAT News | Foundayo competitive read-through: oral Wegovy at ~50K weekly scripts may be tracking ahead, but trackers may be undercounting Foundayo. 80% new-to-GLP-1 mix shows "how much of the obesity market there is to still tap into." (The Readout Loud, Apr 30) |
| **Martin Shkreli** | Investor / commentator | Long-term GLP-1 bear: "Eventually GLPs…they're perfect…So Lilly's kind of screwed" once Ozempic/Mounjaro go generic. Bull on JNJ durability. (The a16z Show, Apr 23) |
| **Dr. Marty Makary** | FDA Commissioner | On 503B exclusion proposal: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." (thefly, Apr 30) |
| **Andrew Dudum** | CEO, Hims & Hers | Zepbound vials/KwikPen + Foundayo now prescribable through LillyDirect on the Hims platform. "Today reminds me of Netflix's early days…" (thefly, Apr 23) |
| **David Lee** | CEO, Servier | "We don't have…quarterly earnings that put a lot of pressure on…we can really think about what it really means from a strategic standpoint long term." Largest player in brain cancer post-Day One. (The Readout Loud, Apr 30) |

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Hot Topics

### Eli Lilly (LLY), The Print of the Quarter

- Q1 2026 revenue **$19.8B** vs. consensus $17.8B; non-GAAP EPS **$8.55** vs. $6.79 consensus (52¢ IPR&D drag).
- FY26 revenue guide raised to **$82–85B** from $80–83B; FY26 EPS raised to **$35.50–37.00** from $33.50–35.00. (thefly, Apr 30)
- Mounjaro Q1 ~$8.7B (+125% YoY); Zepbound +$4.2B; Lilly ~60% of US incretin market vs. Novo's ~39%. (heygotrade.com)
- **Foundayo launch:** >20,000 patients started; >80% new to GLP-1; ~35% via DTC. STAT's Allison DeAngelis: "really goes to show how much of the obesity market there is still to tap into." (The Readout Loud, Apr 30)
- **2025 ranking flip:** Lilly became the #1 pharma globally (up from 10th); top-line +45%; Mounjaro and Zepbound contributed $20B of growth. (Citeline, Apr 21)
- Tuck-in M&A: Lilly to acquire **Ajax** (oral Type II JAK2 inhibitor for myelofibrosis) for up to $2.3B. (thefly, Apr 27)

### UnitedHealth (UNH), Turnaround Confirmed

- Q1 stock **+6% to $342.89**; raised FY26 EPS guide to >$18.25; MCR improved to **84%** from 85% prior; Optum Health margins reaffirmed at **6–8%**. (thefly, Apr 21)
- AI commitment: **$1.5B** investment in FY26 AI initiatives. (thefly, Apr 21)
- **Goldman added UNH to US Conviction List May 1**, $435 PT, citing the company "is nearing the bottom of its underwriting cycle for Medicare Advantage" (40% of the business). (thefly, May 1)
- PT raises across the Street post-print: **JPMorgan $420 (from $389), Piper Sandler $420, Oppenheimer $405, Argus upgrade to Buy/$400, Morgan Stanley $395, Wells Fargo $397, RBC $400.** Lone holdout: Baird (Underperform, $287). (thefly, Apr 22–28)
- Standardizing electronic prior authorization across >50% of PA volume, climbing to >70% by year-end 2026. (thefly, Apr 24)

### Compounding Cliff

- **FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list** (Apr 30): "no clinical need for outsourcing facilities to compound these drugs from bulk substances." (FDA via thefly, Apr 30)
- Earlier in the week: BPI halted GLP-1 production (Apr 23), following ProRx (Apr 8). 503As capped at 4 scripts/month per Apr 2 FDA enforcement memo. (On The Pen, Apr 23)
- Lilly–Hims distribution: Hims & Hers expanded LillyDirect access to **Zepbound vials, KwikPen, and Foundayo**; HIMS +7% pre-market on the news. BofA raised PT to $32. (thefly, Apr 23–24)

### Medicare BALANCE Model, Effectively Stalled

- Apr 20 was the deadline for Medicare insurers to opt in. **CVS opted out**; Lilly/Novo dropped 3% / 2%. (thefly, Apr 21)
- UNH's Bobby Hunter cited "notable challenges and outstanding questions with the currently planned structure." (thefly, Apr 21)
- The original $245/month Medicare price + $50 copay structure now indefinitely delayed; Bridge program extended through end of 2027 at potentially "tens of billions" in federal cost (Elaine Chen, STAT). (The Readout Loud, Apr 23)

### 2025 Global Drug Sales Reshuffle (Citeline, Apr 21)

- **Keytruda #1 at $31.6B** (+7%), with 2028 patent expiry; Keytruda Culex (sub-Q) targeted for ~⅓ of Keytruda sales by 2030.
- **Mounjaro #2** (sales doubled YoY).
- **Ozempic #3** (still grew ~$2B; "may have been Ozempic's last year of growth").
- **Dupixent #4**; Zepbound #9 ($13.6B FY25); Pfizer slipped to #2 company globally on $1.2B revenue decline (sole top-12 decliner).

---

## Key Debates (Bull vs. Bear)

### Debate 1: GLP-1 Long-Term Equity Value

- **Bull (Goldman / STAT):** Foundayo's 80% new-to-GLP-1 mix proves massive untapped TAM; LLY raising into +56% growth quarter; pricing reductions reliably translate into volume. (Closing Bell, Apr 27)
- **Bear (Shkreli):** "Eventually GLPs…they're perfect…Ozempic going generic. Mounjaro eventually…going generic. So Lilly's kind of screwed." Consumers have "zero brand identity." (The a16z Show, Apr 23)

### Debate 2: Foundayo vs. Oral Wegovy Launch Trajectory

- **Bear read (STAT/Chen):** Novo's oral Wegovy reportedly ~50K weekly scripts "a few weeks into launch" vs. Foundayo's >20K total starts so far, "Wegovi pill launch may have been going stronger." (The Readout Loud, Apr 30)
- **Bull read (STAT/Feuerstein + Goldman):** Tracker services "may be undercounting Foundayo." Goldman is "very comfortable" with the consensus number. (The Readout Loud, Apr 30)

### Debate 3: Compounding Crackdown, Branded Tailwind or Patient-Access Risk?

- **Bull (LLY/NVO):** 503B shutdowns + FDA bulks-list exclusion accelerate brand recapture.
- **Bear (Hemi):** "If people literally can't get their prescriptions, it's more likely to be gray [market]…a lot of people on compounded medication genuinely can't afford the Lilly Direct numbers." (On The Pen, Apr 23)

### Debate 4: UNH, Buy the Turnaround or Wait for Stars/2028 Notice?

- **Bull (Goldman Conviction List, JPM, Piper, Argus):** MA cycle bottoming; conservative guide; OptumHealth strength removes downside multiple case. (thefly, Apr 22–May 1)
- **Bear (Baird, Underperform $287):** OptumHealth fine but "Insight remains concerning"; BofA Neutral awaiting visibility on Stars and 2028 MA rate notice. (thefly, Apr 22)

### Debate 5: In Vivo vs. Ex Vivo CAR-T

- **Bull (Roberts/Venrock):** Colonia ASH data (4/4 MM patients in MRD-negative CR) suggests "ex vivo is done" if results hold; targeting 70× return. (The Readout Loud, Apr 23)
- **Counter:** Ex vivo CAR-Ts (Carvykti tracking to $5–6B in 2029–30) still own commercial momentum; viral vs. LNP delivery represent distinct risk profiles.

### Debate 6: FDA Real-Time Trial Data Review (AZ, AMGN pilot)

- **Pro:** Faster approvals, better safety signal-detection.
- **Con (Chen/STAT):** "Interim results don't always translate to the final outcomes…would we be advancing some programs too quickly?" (The Readout Loud, Apr 30)

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Emerging Themes

1. **The "Pivot to Pills" reframes the obesity TAM.** With Foundayo's 80% new-to-GLP-1 mix and Hims/LillyDirect distribution, oral GLP-1s are positioned to expand the addressable population well beyond injectable adopters.
2. **MFN pricing is starting to bite at the franchise level.** Novo Nordisk guided to **5–13% sales decline** in 2026, primarily attributed to its US MFN agreement. The White House completed MFN deals with all 17 named pharma companies (Regeneron last). (Citeline, Apr 21 / Telltales, Apr 29)
3. **Pharma–AI infrastructure deals are now a recurring capex line.** Lilly + NVIDIA $1B/5-yr SF Bay AI lab; Novartis CEO joined Anthropic's board; Novo–OpenAI integration; Novartis–Relation deal "potentially worth over $1.75B." (Citeline, Apr 27)
4. **Mid-cap pharma as M&A acquirer cohort.** Cooley's Bill Roegge: BioMarin, Neurocrine, Lundbeck, Jazz, BioNTech, Lantheus, Genmab "have done billion-plus deals recently." (Citeline, Apr 22)
5. **China in-licensing has gone from anecdote to structural.** Notable example: Kylera's ribupetide platform fully in-licensed from Hengrui. (Citeline, Apr 27)
6. **LP(a) emerging as next major cardiovascular battleground.** Goldman: "We don't even have placeholders in our models outside of Novartis for these drugs right now." Watch Amgen and Lilly CERNAS programs. (Closing Bell, Apr 27)
7. **Generics manufacturers as patent-cliff beneficiaries.** Telltales' Wallace: "the winner of [patent cliffs] is the generics manufacturers." Teva's pivot fits this thesis, with the third-largest biosimilar portfolio in the world. (Telltales, Apr 29 / CNBC Money Movers, Apr 29)
8. **Iran blockade / freight disruption is the supply-chain wildcard.** Freight rates "nearly doubled"; Asian solvent costs spiking; ASHP's Gagneau: no immediate impact yet, but contract drug manufacturers may invoke "force majeure clauses." (Citeline, Apr 27)

---

## Deals & M&A Tracker

| Deal | Value | Date | Notes / Source |
| --- | --- | --- | --- |
| **Boston Scientific / Penumbra (PEN)** | $14.5B | Q1 2026 | Largest disclosed Q1 2026 healthcare deal. (businessinsider.com) |
| **Sun Pharma / Organon** | ~$12B | Apr 2026 | Women's health. (Citeline, Apr 22) |
| **Gilead / Arcellx** | $7.8B | Feb 2026 | Cancer cell therapy. |
| **Merck / Terns Pharmaceuticals** | $6.7B | Mar 25, 2026 | Bolster Keytruda franchise. |
| **Eli Lilly / Centessa Therapeutics** | $6.3B upfront | Mar 31, 2026 | Sleep disorders. |
| **Eli Lilly / Colonia Therapeutics** | $3.25B upfront (~$6.5B incl. milestones) | Apr 2026 | In vivo CAR-T; updates expected at ASCO end of May. |
| **Biogen / Apellis** | $5.6B | Mar 31, 2026 | Complement inhibitors. |
| **Neurocrine / Celino** | $2.9B | Apr 6, 2026 | Neuroscience. |
| **Servier / Day One Biopharmaceuticals** | $2.5B | Apr 2026 | Pediatric brain cancer; positions Servier as largest brain-cancer player. |
| **Eli Lilly / Ajax** | up to $2.3B | Apr 27, 2026 | Oral Type II JAK2 inhibitor (myelofibrosis). (thefly, Apr 27) |
| **Teva / Emilex Biosciences** | undisclosed | Apr 29, 2026 | Tourette syndrome (EcoPiPan, Phase 3 complete), Teva's first M&A in 10 years. (CNBC Money Movers, Apr 29) |
| **Quantum Health / CirrusMD** | undisclosed | Apr 2026 | Virtual care consolidation. |
| **MKH Capital / Haven Health Mgmt** | undisclosed | Apr 2026 | Behavioral health. |

**Industry M&A firepower** ~$650B (Goldman/Haider, levered ~2.5× EBITDA). Lilly alone closed 3× $1B+ deals + 7 alliances in Q1 2026, "Lilly is doing these deals from a position of strength" (Roegge). (Closing Bell, Apr 27 / Citeline, Apr 22)

**Biggest IPO of the year:** **Kylera Therapeutics** grossed $625M on Apr 16 (potentially $718.8M with overallotments), closing **+63%** on day one, potentially the largest US drug-developer IPO ever. Ribupetide (GLP-1/GIP) Phase 3 obesity data expected 2028. (Citeline, Apr 27)

```request-access
variant: inline
heading: Want this kind of synthesis on your own coverage?
buttonText: Request access
```

## Regulatory Watch

- **FDA proposes to exclude semaglutide, tirzepatide, liraglutide from the 503B bulks list (Apr 30)**, Commissioner Makary: "When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." (thefly, Apr 30)
- **FDA approves Axsome's Auvelity for Alzheimer's agitation (Apr 30)**, only the second drug approved for this indication. (neurologylive.com)
- **Travere Therapeutics / Filspari approved (Apr 13)**, first FDA-approved drug for FSGS (~40K US patients); Travere holds monopoly. (Citeline, Apr 21)
- **Revolution Medicines daraxonrasib Phase 3**, pancreatic cancer OS 13.2 mo vs. 6.7 mo control; Evercore's Kazimov: "unequivocally practice-changing." Filing imminent; possible 2026 launch. (Citeline, Apr 21)
- **Recent gene-therapy approvals:** Rocket's Kresladi (LAD-I); Otarmeni (OTOF hearing loss).
- **FDA real-time data review pilot**, starting with AZ and Amgen oncology trials on Paradigm Health platform; broader pilot in summer 2026. (The Readout Loud, Apr 30)
- **Medicare BALANCE Model effectively stalled** after CVS and other insurers declined to opt in by the Apr 20 deadline. (thefly, Apr 21)
- **Prior authorization reform**, UnitedHealthcare scaling standardized e-PA to >70% of volume by year-end. (thefly, Apr 24)
- **Most-Favored-Nation pricing**, White House completed MFN contracts with all 17 named pharma companies; Regeneron last to sign. (Telltales, Apr 29)
- **Lilly v. Mochi Health**, federal judge denied Mochi's motion to dismiss; discovery proceeding. (On The Pen, Apr 23)

---

## Week Ahead

- **Wed, May 6, Novo Nordisk Q1 2026 earnings.** Read-throughs: oral Wegovy script trajectory, US MFN impact on guide (already framed at -5 to -13%), defense vs. Foundayo. (heygotrade.com)
- **Imminent FDA decisions:** Grace Therapeutics' IV nimodipine (GTx-104) for aneurysmal SAH; rare-disease readouts including Regenxbio's RGX-121 for Hunter syndrome. (primetherapeutics.com)
- **End of May, ASCO 2026.** Watch: Colonia / Lilly in vivo CAR-T myeloma update; Merck next-gen oncology targets; Revolution Medicines daraxonrasib filing momentum.
- **Friday morning Foundayo script tracking.** Goldman: "Investors are going to be scrutinizing every Friday morning…what these script trends look like." (Closing Bell, Apr 27)
- **Bristol-Myers, Merck, Cigna earnings already underway** (BMY consensus $1.42; MRK ($1.47) loss; CI $7.60). (thefly, Apr 29)
- **GSK B7H4 ADC (MORES)** Phase 3 starts "in the next few months" (5 trials).
- **Compounding transition window.** With FDA bulks-list exclusion proposed Apr 30 and the BPI/ProRx 503B shutdowns, expect supply disruption signals over the next 30–60 days; Lilly Direct / gray-market monitoring required.

---

## Sources

- The Readout Loud, Apr 23 & Apr 30
- Closing Bell, Apr 27
- CNBC Money Movers, Apr 29
- On The Pen, Apr 23
- The a16z Show, Apr 23
- Citeline, Apr 21, Apr 22 & Apr 27
- Telltales, Apr 29
- thefly, Apr 21–May 1

*This digest is based on podcast, news, and web sources from April 21 – May 1, 2026. It is for informational purposes and does not constitute investment advice.*

```request-access
variant: banner
heading: Run your own corpus.
description: matterfact is deployed with select institutional partners. Request access to run it on your own coverage.
buttonText: Request access
```